|

nab-paclitaxel + gemcitabine Clinical Trials

5 actively recruiting trials across 1 location

▲ +1 trial since July 2026

Pipeline

Phase 2: 2Phase 3: 1Phase 1/2: 2

Top Sponsors

  • Theriva Biologics SL1
  • Jiangsu HengRui Medicine Co., Ltd.1
  • Fudan University1
  • Dartmouth-Hitchcock Medical Center1
  • Chinese PLA General Hospital1

Indications

  • Cancer5
  • Ductal Adenocarcinoma of the Pancreas1
  • Pancreas Cancer, Metastatic1
  • Pancreas Cancer, Stage IV1
  • First-line Treatment of Metastatic Pancreatic Cancer1

Other4 trials

A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Cancer
Phase 2
A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer
Phase 1/2
Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer
Phase 3
Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
Phase 1/2

Lebanon, New Hampshire1 trial

24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC

Dartmouth-Hitchcock Medical Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.